Standard Biotools Stock Investor Sentiment
| LAB Stock | USD 1.28 0.03 2.40% |
About 69 percent of all Standard Biotools' investors are curious in acquiring. The analysis of overall sentiment of trading Standard Biotools stock suggests that quite a large number of investors are confidant at this time. The current market sentiment, together with Standard Biotools' historical and current headlines, can help investors time the market. In addition, many technical investors use Standard Biotools stock news signals to limit their universe of possible portfolio assets.
Comfort Level 69
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Standard Biotools' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Standard Biotools.
News SentimentBullish | Hype SentimentBullish | Insider SentimentAcquiring |
Standard Historical Sentiment
Although Standard Biotools' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Standard, such as negative comments on social media and news outlets, may cause fear in the market and push Standard Biotools' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Standard.
Standard Biotools Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Standard Biotools can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Standard Biotools Historical Investor Sentiment
Investor biases related to Standard Biotools' public news can be used to forecast risks associated with an investment in Standard. The trend in average sentiment can be used to explain how an investor holding Standard can time the market purely based on public headlines and social activities around Standard Biotools. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Standard Biotools' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Standard Biotools and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Standard Biotools news discussions. The higher the estimate score, the more favorable the investor's outlook on Standard Biotools.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Standard Biotools' Stock prices. Below is the latest headlines and news related to Standard Biotools Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Standard Biotools that are available to investors today. This information is accessible both publicly - through Standard Biotools' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Standard-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Standard Biotools news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Standard Biotools relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Standard Biotools' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Standard Biotools alpha.
Standard Largest EPS Surprises
Earnings surprises can significantly impact Standard Biotools' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-06 | 2025-03-31 | -0.04 | -0.0478 | -0.0078 | 19 | ||
2025-02-26 | 2024-12-31 | -0.03 | -0.0494 | -0.0194 | 64 | ||
2024-10-30 | 2024-09-30 | -0.09 | -0.07 | 0.02 | 22 | ||
2013-02-12 | 2012-12-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2019-05-02 | 2019-03-31 | -0.25 | -0.28 | -0.03 | 12 | ||
2012-11-07 | 2012-09-30 | -0.21 | -0.18 | 0.03 | 14 |
There is far too much social signal, news, headlines, and media speculation about Standard Biotools that are available to investors today. This information is accessible both publicly - through Standard Biotools' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Standard-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Standard Biotools news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Standard Biotools relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Standard Biotools' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Standard Biotools alpha.
Standard Biotools Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | XDENT LAB Officially Joins the NADL as a Supplier Member | 10/10/2025 |
2 | Acquisition by Casdin Partners Master Fund, L.p. of 100000 shares of Standard Biotools at 1.2892 subject to Rule 16b-3 | 10/15/2025 |
3 | Standard BioTools Profitability Challenges Persist Despite Attractive Price-to-Sales Ratio | 11/06/2025 |
4 | Acquisition by Casdin Partners Master Fund, L.p. of 225000 shares of Standard Biotools at 1.1234 subject to Rule 16b-3 | 11/07/2025 |
5 | Acquisition by Casdin Partners Master Fund, L.p. of 375000 shares of Standard Biotools at 1.1889 subject to Rule 16b-3 | 11/12/2025 |
6 | Acquisition by Casdin Partners Master Fund, L.p. of 250000 shares of Standard Biotools at 1.2392 subject to Rule 16b-3 | 11/14/2025 |
7 | CoapTech Announces Leadership Transition Board Appoints Brad Kreger as Chief Executive Officer, CoFounder and CEO Howard Carolan Steps Down | 11/18/2025 |
8 | Acquisition by Casdin Partners Master Fund, L.p. of 450000 shares of Standard Biotools at 1.3028 subject to Rule 16b-3 | 11/20/2025 |
9 | Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4325 subject to Rule 16b-3 | 11/24/2025 |
10 | Casdin Partners Master Fund, L Buys 7,550,000 Shares of Standard BioTools Stock | 11/26/2025 |
11 | Acquisition by Casdin Partners Master Fund, L.p. of 125000 shares of Standard Biotools at 1.4201 subject to Rule 16b-3 | 12/02/2025 |
12 | EY announces rollout of new physical AI platform, opening of EY.ai Lab and EY Global Robotics and Physical AI leader appointment | 12/03/2025 |
13 | Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4468 subject to Rule 16b-3 | 12/04/2025 |
14 | GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT | 12/09/2025 |
15 | Tomorrow Lab Co-Hosts An Informal Party to Rock CES at The Punk Rock Museum | 12/17/2025 |
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |